ABT (Abbott Laboratories) — AI Stock Analysis & Recommendation

Research of August 6, 2026 · Healthcare / Pharmaceutical Preparations

TradeFlare's AI research teams rate ABT a BUY. The latest price is $102.61.

The research plan

• Entry: $107.96
• Time horizon: N/A

N/A

Why

While there are some bullish sentiment indicators and a recent bullish MA crossover, the high risk score, significant earnings decline, and conflicting technical signals prevent a buy recommendation. The stock is currently consolidating, and the risks associated with operational issues and past volatility outweigh the immediate bullish signals. A HOLD is appropriate until clearer technical or fundamental catalysts emerge.

What could push ABT higher

• Positive analyst sentiment driven by strong earnings and raised guidance.
• Potential for earnings recovery as suggested by forward P/E.
• Bullish MA crossover indicating potential upside momentum.

Key risks for ABT

• Significant year-over-year earnings decline (-47.5%) despite revenue growth.
• High risk score (7/10) due to operational risks (infant formula recall), deep 1-year drawdown, and sector regulatory risk.
• Conflicting technical signals with MACD showing bearishness while other indicators are mixed.

What each AI research team found

Fundamental team: Neutral · valuation: fair

Abbott Laboratories presents a mixed fundamental picture, with strong revenue growth and a diversified business model offset by a significant decline in earnings. While the current valuation appears fair based on forward P/E and analyst expectations of recovery, the earnings weakness introduces risk. The company's robust cash flow and competitive strengths provide a solid foundation, but a sustained recovery in...

• Significant year-over-year earnings decline (-47.5%) is a major concern despite positive revenue growth (13% YoY).
• Forward P/E of 17.8x suggests the market expects an earnings recovery, making the current valuation appear fair.
• Strong Free Cash Flow generation (16.35% margin) and manageable debt levels provide financial stability.

Technical team: Neutral

ABT is currently in a neutral consolidation phase with conflicting signals from momentum indicators. While chart patterns suggest potential for a short-term move towards resistance, the lack of strong volume and bearish MACD signal warrant caution. A decisive move above $111.30 would be needed to confirm a bullish trend.

• The price is consolidating between support and resistance, with a recent bullish MA crossover suggesting potential upside, but the overall trend remains uncertain.
• The stock is consolidating with mixed volume signals, suggesting a neutral outlook until a clear breakout or breakdown occurs.
• Momentum indicators are mixed, with MACD suggesting bearishness while RSI and Stochastic are neutral, indicating a sideways trend with potential for a short-term move towards the nearest support level.

Sentiment team: Bullish

The overall sentiment for ABT is bullish, supported by strong analyst ratings, positive news regarding earnings and guidance, and a cautiously optimistic social media outlook. While concerns around leverage and the nutrition segment persist, the company's core growth drivers and strategic acquisitions are providing a positive tailwind.

• Abbott Laboratories (ABT) exhibits a cautiously optimistic sentiment driven by a recent earnings beat and raised guidance, strong performance in key growth segments, and positive analyst outlooks, despite ongoing concerns in its nutrition business and...
• Retail investor sentiment for ABT is cautiously optimistic, balancing concerns over specific segment weaknesses and acquisition debt against its attractive valuation, strong dividend, and potential for recovery in core businesses. (score: 0.05)
• Abbott Laboratories exhibits a positive sentiment driven by strong earnings, raised guidance, and a predominantly bullish analyst consensus, though concerns exist regarding increased leverage and a recent credit rating downgrade.

Risk team: High

Abbott Laboratories (ABT) presents a HIGH risk profile primarily due to significant operational and legal risks associated with its infant formula business, compounded by high historical volatility and a substantial past drawdown. While the company has a strong market position, the ongoing litigation and potential for further operational issues necessitate a cautious approach and a SMALL position size.

• Operational Risk (Infant Formula Recall & Litigation): Significant operational disruptions and ongoing litigation stemming from the infant formula recall present substantial legal and financial risks.
• Deep 1-Year Drawdown & Elevated Realized Volatility: The stock has experienced a severe drawdown and exhibits very high historical volatility, indicating a high propensity for sharp price declines.
• Sector Regulatory Risk: As a healthcare company, ABT is susceptible to regulatory changes that can impact product approvals and market access.

ABT at a glance

Market value	$169.8B
Price / earnings	27.2
Revenue growth (year over year)	6.6%
Profit margin	13.9%
Debt / equity	0.57

TradeFlare's published calls on ABT

• July 21, 2026: closed after 45 days, +0.9%

Every AI call on ABT since April 28, 2026, and what happened next (13 calls) →

Research of August 6, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.